Skip to content

Light on COVID-19

Shining Light on COVID-19 - : Shining Light on COVID-19

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
REBEC
Registry ID
RBR-2z5t7z
Enrollment
Unknown
Registered
2020-11-16
Start date
2020-10-04
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Virus diseases, of unspecified location

Interventions

Volunteers will be divided into 2 groups, composed of 20 patients each group, distributed at random, as appropriate. The sets will be formed by patients with SARS-Cov-2, treated with infrared LED (940
Device
Radiation

Sponsors

Anhembi Morumbi
Lead Sponsor
Anhembi Morumbi
Collaborator

Eligibility

Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: The research will include patients: aged between 60 and 80 years; with clinical diagnosis of SARS-Cov-2; undergoing medical treatment at Santa Casa de Pindamonhangaba and Itajubá; in invasive mechanical ventilation and in drug treatment.

Exclusion criteria

Exclusion criteria: Patients will not be part of the research: institutionalized; overweight (Body Mass Index - BMI: above 29.9 kg / m2); without the signature of the person responsible for the IC; do not belong to the mentioned age group; who have neoplasms and a history of photosensitivity.

Design outcomes

Primary

MeasureTime frame
It is expected that the association of photobiostimulation techniques with low light power, using LEDs in the red-infrared light band and conventional treatment of respiratory physiotherapy are effective in improving lung function, ventilatory mechanics and inspiratory and expiratory muscle strength for the treatment of patients with sars-cov-2, in addition to optimizing the clinical condition of the patient with repercussions on respiratory rate and pulse oximetry.

Secondary

MeasureTime frame
With the use of the photobiomodulation technique associated with respiratory physiotherapy, he hopes to find a decrease in hospital costs and mortality rates.

Countries

Brazil

Contacts

Public ContactPâmela Pereira

Centro Universitário de Itajubá

pam_milaf@yahoo.com.br+55-35-991478959

Outcome results

None listed

Source: REBEC (via WHO ICTRP)